ReproCell Stock

ReproCell Assets per Share

The Total Assets per Share of ReproCell (4978.T) as of Sep 4, 2026 is 104.15 JPY. In the previous year, Total Assets per Share was 97.49 JPY — a change of 6.83% (higher).

Assets per Share

104.15JPY

YoY

6.83%

Last updated:

Total Assets per Share of ReproCell is 2026 104.15 JPY. Total Assets per Share of ReproCell was 2025 97.49 JPY. It decreases by 6.83% higher compared to the previous year.

The ReproCell Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
71.06 JPY
Jan 1, 2019
80.67 JPY
Jan 1, 2020
70.57 JPY
Jan 1, 2021
65.13 JPY
Jan 1, 2022
87.18 JPY
Jan 1, 2023
89.99 JPY
Jan 1, 2024
97.49 JPY
Jan 1, 2025
104.15 JPY
The ReproCell Assets per Share history
YEARAssets per ShareYoY
104.15JPY+6.83%
97.49JPY+8.34%
89.99JPY+3.22%
87.18JPY+33.86%
65.13JPY-7.71%
70.57JPY-12.51%
80.67JPY+13.52%
71.06JPY-16.00%
84.59JPY-1.43%
85.82JPY+4.92%
81.79JPY+40.15%
58.36JPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Total Assets per Share of ReproCell is 104.15 JPY in 2026.

Total Assets per Share of ReproCell changed from 97.49 JPY to 104.15 JPY, representing a 6.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share ReproCell since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

Other — ReproCell

All Key Metrics — ReproCell